Chong Kun Dang gears up on first generic of ‘Revlimid’ recording KRW 7 trillion
Chong Kun Dang was approved to conduct bioequivalent tests for approval of the first generic of ‘Revlimid(generic name: lenalidomide, Celgene),’ a multiple myeloma therapy whose substance patent will be expired next year.
Revlimid recorded approximately USD 6 billion sales in the global market. ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
